Journal of Nephropharmacology最新文献

{"title":"Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial","authors":"M. Pourahmad, Amir Aria, M. Momenzadeh, Fatemeh Nikoukar, B. Ataei, F. Khorvash, Manizhe Shams, K. Shahzamani, Sara Nasirharandi","doi":"10.34172/npj.2023.11650","DOIUrl":"https://doi.org/10.34172/npj.2023.11650","url":null,"abstract":"Introduction: COVID-19 is associated with a cascade of inflammatory responses potentially lead to devastating outcomes. Objectives: The current study aims to investigate the efficacy of montelukast, a leukotriene receptor antagonist (LTRA), on laboratory parameters in COVID-19 infection. Patients and Methods: The current randomized clinical trial (RCT) conducted on 67 patients with moderate-to-severe COVID-19 pneumonia in 2020-2021. All patients received treatments according to the national guidelines, while the case group additionally applied 10 mg montelukast for 14 days. The clinical disease improvement and laboratory data (complete blood cells count and differentiation, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer, blood urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) were assessed within two weeks after the infection and compared between the groups. Results: Baseline assessed parameters did not differ between the groups (P>0.05). A significant decrease in pulse rate, also in normal ranges, was notified in the montelukast-treated group compared with the baseline (P=0.001) and with controls (P=0.033); however, other vital signs were not statistically different (P>0.05). CRP (P<0.001), ESR (P=0.008), BUN (P=0.015), and AST (P<0.001) significantly decreased in the post-intervention assessment of the montelukast-treated group. The comparison of the groups in post-intervention reviews revealed significantly lower CRP (P=0.042) and D-dimer (P=0.008) in the intervention group versus controls. Conclusion: Based on the findings of this study, montelukast use with a daily dose of 10 mg for 14 days could remarkably decrease inflammatory indices in patients with COVID-19 pneumonia. Further studies on this issue are strongly recommended. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20181208041886N3, https://www.irct.ir/trial/51633; ethical code #IR.MUI.MED. REC.1399.382).","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140490383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mayo Clinic consensus report on membranous nephropathy; a promising step toward better treating the disease","authors":"S. Zandifar, Leila Alem, Azadeh Khayyat, Mohammad Ali Esmaeil pour","doi":"10.34172/npj.2023.11657","DOIUrl":"https://doi.org/10.34172/npj.2023.11657","url":null,"abstract":"Membranous nephropathy is an immune complex disease caused by subepithelial deposits. The pathological manifestations of membranous nephropathy are considered by the creation of immune complexes in the epithelial cells of the glomerular basement membrane. The established pathologic features of primary membranous nephropathy include subepithelial immune deposits, thickening of the glomerular basement membrane, and podocyte foot process effacement. The clinical implications of pathological features of primary membranous nephropathy include male gender, age, persistent heavy proteinuria, decreased glomerular filtration rate on presentation, and tubulointerstitial fibrosis. Membranous nephropathy is diagnosed through a kidney biopsy, confirming subepithelial immune deposits, thickening of the glomerular basement membrane, and podocyte foot process effacement.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal insufficiency in breast cancer patients; a review study","authors":"N. Moradi, Shahrzad Izadi, H. Hemmati","doi":"10.34172/npj.2024.11659","DOIUrl":"https://doi.org/10.34172/npj.2024.11659","url":null,"abstract":"The latest statistics and estimations indicated that breast cancer occurs in one-fourth of women worldwide and is responsible for one in six cancer deaths among women. A bilateral relationship seems to exist between breast cancer pathophysiology and kidney failure. Consideration should be given to this relationship when selecting a treatment protocol. This paper reviews the association between these two factors in breast cancer patients. There are many aspects to consider in the association between breast cancer and renal insufficiency. A breast cancer patient with normal kidney function is at risk of developing kidney failure due to paraneoplastic syndromes, hypercalcemia, and in rare cases, tumor lysis syndrome (TLS). In defining the optimal treatment protocol for each breast cancer patient, clinicians should consider the patient’s basal glomerular filtration rate (GFR). Frequent renal clearance monitoring and taking immediate action at the time GFR begins to decrease will lower the rate of kidney failure in breast cancer patients. Lastly, patients with chronic kidney disease who are recently diagnosed with breast cancer may have higher morbidity and mortality compared to breast cancer patients with normal GFR. Further investigation is needed to lower morbidity and mortality in such patients.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139531235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncocardiology: close collaboration between oncologists, cardiologists, and nephrologists","authors":"Sina Salati, Bahare Firouzbakht, Padideh Daneii, Ali Azarpey, Behnaz Hatami, Mohamad Mehdi Johari Moghadam, Negar Jafari","doi":"10.34172/npj.2023.11660","DOIUrl":"https://doi.org/10.34172/npj.2023.11660","url":null,"abstract":"Cancer treatment can lead to combined heart and kidney complications, which can have a significant impact on patient outcomes. Chemotherapy and radiation therapy used to treat cancer can cause damage to both the heart and kidneys, leading to a range of complications. Managing combined heart and kidney complications following cancer treatment requires a collaborative and multidisciplinary approach, with regular monitoring and personalized management plans tailored to the individual patient’s needs.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139213093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology","authors":"S. Zandifar, Sadaf Farnam Nia, Rastina Mehrani, Bina Bakhshaei, Samin Karamian, Sina Bagheri, Ali Ghorbani, Sina Bakhshaei","doi":"10.34172/npj.2023.11648","DOIUrl":"https://doi.org/10.34172/npj.2023.11648","url":null,"abstract":"Implication for health policy/practice/research/medical education: Reverse cardio-oncology addressed the risk of ensuing cancer in individuals with heart disease. It is imperative to collaborate oncology with cardiology to effectively prevent and treat related diseases","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139212792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of risk factors affecting the lifespan and efficiency of dialysis accesses installed in dialysis patients referees to Ahvaz therapeutic centers in a two-year cohort study","authors":"Afshin Bighamian, I. Nazari, Seyed Masood Mousavi, Hossain Minaee","doi":"10.34172/npj.2023.10639","DOIUrl":"https://doi.org/10.34172/npj.2023.10639","url":null,"abstract":"Introduction: It is crucial in order to provide optimal hemodialysis to patients with end-stage renal disease (ESRD) to establish venous access with the least amount of complications. Objectives: In this study, we examined the risk factors that affect the efficiency and longevity of dialysis access for patients receiving dialysis in Ahvaz medical centers. Patients and Methods: In our retrospective study, 180 hemodialysis patients were referred to the Golestan educational and medical center in Ahvaz, Iran. An arteriovenous fistula (AVF) or catheter was conducted to provide them with vascular access. Detailed demographic information about the patient was collected, including age, gender, height, weight, body mass index (BMI), cause of ESRD, duration of renal failure, duration of dialysis, and comorbidities. There were instances of access inefficiency as a result of infection, stenosis, closure, thrombosis, bleeding, and pseudoaneurysms. The data was analyzed using Mann-Whitney U, t test, and chi-square tests with SPSS version 22. Statistics were considered significant at a P value of 0.05. Results: The mean age of the patients was 50.08 ± 12.213 years, and the mean BMI was 27.90 ± 9.112 kg/m2 . Among dialysis patients, there was a significant relationship between male gender, clopidogrel administration, diabetes history, hypertension and access failure. It is estimated that 36.7% of vascular access failures are caused by thrombosis, while 32.8% are due to access stenosis or closure. Conclusion: Our study showed that male gender, clopidogrel administration, and a history of diabetes and hypertension were risk factors affecting dialysis access quality and efficiency. According to our study, it may be possible to develop a more appropriate approach for determining the type and location of dialysis access.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139216832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should a forgotten guidewire be removed after years? An undesirable complication of hemodialysis catheter wire left in the body","authors":"M. Hekmat, H. Ghaderi, Zahra Ansari Aval, S. Mirjafari, R. Tirdad","doi":"10.34172/npj.2023.11649","DOIUrl":"https://doi.org/10.34172/npj.2023.11649","url":null,"abstract":"Today, one of the most common methods used in the emergency room or intensive care unit (ICU) in patients is the Seldinger technique to access the central venous system, shunting for hemodialysis, intra-aortic balloon pump, or arterial insertion. Accidental leaving of the guide wire is an uncommon but important complication that can occur as a result of an incorrect technique, and it is sometimes found accidentally or due to complications years after the procedure. The case is a 53-year-old patient who underwent aortic valve replacement with a mechanical valve and mitral valve repair with a ring 12 years ago and was treated with warfarin. Two years after the heart surgery, due to chronic renal failure, the patient underwent dialysis, and after the preparation of an arteriovenous fistula, he underwent stenting. After approximately ten years, the patient developed fever, chills, and shortness of breath. During the examination, endocarditis was diagnosed, and a part of the aortic valve was released. There was a severe paravalvular leak in the aortic valve, and an abscess was formed in the aorta root. We also noticed a forgotten guide wire in the superior vena cava, right atrium, inferior vena cava, and hepatic vein, and echogenic masses were located on the guidewire. The diagnosis was confirmed by echocardiography, chest x-ray, and phenocopy. After antibiotic therapy, the patients underwent heart surgery, aortic valve replacement, and aortic root repair, and the guidewire was removed (70 cm long). Unfortunately, despite all measures, the patient died a few days after the surgery. Due to complications, a forgotten guidewire should be removed immediately after diagnosis. The preferred intervention is the removal of the guidewire by endovascular interventions, but surgical treatment should also be considered in some cases.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139216684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of N-acetylcysteine for contrast-induced acute kidney injury; an updated mini-review","authors":"S. Mirfendereski, Mahboubeh Taghipour, Farshad Yadollahi, Hadi Taghavinejad, Mahdieh Ahmadnia","doi":"10.34172/npj.2023.11658","DOIUrl":"https://doi.org/10.34172/npj.2023.11658","url":null,"abstract":"Contrast-induced acute kidney injury (CI-AKI) is a potential complication of medical imaging procedures that use contrast media. It is important to identify and manage risk factors for contrast-induced nephropathy and to monitor patients for signs of renal damage after contrast administration. N-acetylcysteine (NAC) can prevent CI-AKI through multiple mechanisms of action, including reducing oxidative stress, improving renal hemodynamics, reducing inflammation, reducing apoptosis and fibrosis, reducing oxidative stress-induced DNA damage, reducing tubular cell injury, and reducing renal tubular cell apoptosis. However, the exact mechanisms of action may vary based on the specific study or context. Further research is needed to fully elucidate the molecular mechanisms of NAC in preventing CI-AKI.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139223769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between metformin administration and non-Hodgkin lymphoma; a systematic review and meta-analysis of cohort and case-control studies","authors":"Elnaz Ataei, Razieh Bagheri Shahzadeh Aliakbari, Navid Asgari, Nasim Zaman Samghabadi, Sina Salati, Sara Abbasian, Mohammad Akbari, Farshad Gharebakhshi, Anna Ghorbani Doshantapeh","doi":"10.34172/npj.2023.11651","DOIUrl":"https://doi.org/10.34172/npj.2023.11651","url":null,"abstract":"Introduction: Metformin, a blood sugar-lowering agent, has the potential to be an anti-cancer agent. However, its role in lymphoma remains uncertain. Objectives: This study sought to examine the correlation between the utilization of metformin and non-Hodgkin lymphoma through the application of a systematic review and meta-analysis methodology. Materials and Methods: This investigation was carried out in the form of a methodical examination and meta-analysis in accordance with the PRISMA guidelines. Databases such as Scopus, PubMed, Web of Science, Cochrane, and the Google Scholar search engine were thoroughly explored without any temporal limitations until September 20, 2023. The data was analyzed utilizing the STATA 14 software, and the level of significance for the tests was established at P<0.05. Results: The results, obtained by combining six observational studies (five cohort studies and one case-control study) with a total sample size of 2 330 787 individuals, showed that the odds ratio (OR) for the association between metformin use and non-Hodgkin lymphoma in all studies was 0.91 (95% CI: 0.78, 1.07). In cohort studies, the OR was 0.91 (95% CI: 0.74, 1.11), and in the case-control study, it was 0.93 (95% CI: 0.79, 1.10). None of these relationships were statistically significant. The odds ratio between metformin uses and chronic lymphocytic leukemia/small lymphocytic leukemia was 0.93 (95% CI: 0.71, 1.21), and the odds ratio between metformin use and diffuse large B-cell lymphoma was 1.06 (95% CI: 0.61, 1.83), both of which were not statistically significant. Conclusion: This investigation’s findings indicated no statistically noteworthy correlation exists between the utilization of metformin and the probability of contracting non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, and diffuse large B-cell lymphoma. Registration: This study was conducted following the PRISMA checklist. Its protocol was registered on the PROSPERO (CRD42023469100) and Research Registry (UIN: reviewregistry1721) websites.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139229570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nephrotoxicity of checkpoint inhibitors; a current challenge","authors":"S. Zandifar, Mahshid Imankhan, Padideh Daneii, Ali Azarpey, Leila Alem","doi":"10.34172/npj.2023.10641","DOIUrl":"https://doi.org/10.34172/npj.2023.10641","url":null,"abstract":"Immune checkpoint inhibitors work by blocking the \"checkpoint\" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system. Consequently, checkpoint inhibitors can cause autoimmune reactions, resulting in adverse effects. Prompt identification and management of adverse effects are critical for patients under checkpoint inhibitor therapy due to the potential severity and unpredictability of these immune-related adverse events.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139255954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}